Search hospitals > Pennsylvania > Abington
Abington Neurological Associates
Claim this profileAbington, Pennsylvania 19001
Global Leader in Alzheimer's Disease
Global Leader in Dementia
Conducts research for Multiple Sclerosis
Conducts research for Cognitive Impairment
Conducts research for Migraine
68 reported clinical trials
1 medical researcher
Summary
Abington Neurological Associates is a medical facility located in Abington, Pennsylvania. This center is recognized for care of Alzheimer's Disease, Dementia, Multiple Sclerosis, Cognitive Impairment, Migraine and other specialties. Abington Neurological Associates is involved with conducting 68 clinical trials across 51 conditions. There are 1 research doctors associated with this hospital, such as David Weisman.Area of expertise
1Alzheimer's Disease
Global LeaderAPOE4 positive
donanemab
APOE
2Dementia
Global Leaderdonanemab
Top PIs
Clinical Trials running at Abington Neurological Associates
Alzheimer's Disease
Multiple Sclerosis
Dementia
Hallucinations
Alzheimer's Dementia
ACP-204
for Alzheimer's Disease
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1. All 3 substudies will be analyzed independently of each other. Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).
Recruiting0 awards Phase 2 & 31 criteria
VHB937
for Alzheimer's Disease
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Recruiting0 awards Phase 24 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Abington Neurological Associates?
Abington Neurological Associates is a medical facility located in Abington, Pennsylvania. This center is recognized for care of Alzheimer's Disease, Dementia, Multiple Sclerosis, Cognitive Impairment, Migraine and other specialties. Abington Neurological Associates is involved with conducting 68 clinical trials across 51 conditions. There are 1 research doctors associated with this hospital, such as David Weisman.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.